Mismatch Repair Deficiency in Ovarian Carcinoma: Frequency, Causes, and Consequences
Mismatch repair deficiency (MMRD) is involved in the initiation of both hereditary and sporadic tumors. MMRD has been extensively studied in colorectal cancer and endometrial cancer, but not so in other tumors, such as ovarian carcinoma. We have determined the expression of mismatch repair proteins in a large cohort of 502 early-stage epithelial ovarian carcinoma entailing all the 5 main subtypes: high-grade serous carcinoma, endometrioid ovarian carcinoma (EOC), clear cell carcinoma (CCC), mucinous carcinoma, and low-grade serous carcinoma. We studied the association of MMRD with clinicopathologic and immunohistochemical features, including tumor-infiltrating lymphocytes in EOC, the histologic type in which MMRD is most frequent. In addition, MLH1 promoter methylation status and massive parallel sequencing were used to evaluate the proportion of sporadic and Lynch syndrome–associated tumors, and the most frequently mutated genes in MMRD EOCs. MMRD occurred only in endometriosis-associated histologic types, and it was much more frequent in EOC (18%) than in CCC (2%). The most frequent immunohistochemical pattern was loss of MLH1/PMS2, and in this group, 80% of the cases were sporadic and secondary to MLH1 promoter hypermethylation. The presence of somatic mutations in mismatch repair genes was the other mechanism of MMRD in sporadic tumors. In this series, the minimum estimated frequency of Lynch syndrome was 35% and it was due to germline mutations in MLH1, MSH2, and M...
Publication date: Available online 14 July 2020Source: Seminars in Cancer BiologyAuthor(s): Rui Caetano Oliveira, Henrique Alexandrino, Maria Augusta Cipriano, Filipe Caseiro Alves, José Guilherme Tralhão
Authors: Feng Z, Feng Z, Han J, Cheng W, Su B, Mo J, Feng X, Feng S, Chen G, Huang P, Huang L, Cui Z Abstract Shenling Baizhu additive powder (SLBZ-AP), a formulation of a variety of natural medicinal plants, has clinical efficacy in treating cancers in previous studies. We explored the effect of SLBZ-AP in bone metastasis of lung cancer (BMLC) mice, and the possible mechanism involved was further investigated in the present study. Mice model of BMLC was made and treated with SLBZ-AP. Pain behavioral tests were performed to explore the effect on BMLC-induced pain in mice. TUNEL staining was used to investigate apop...
Publication date: Available online 13 July 2020Source: Materials Today: ProceedingsAuthor(s): Anita Gupta
Publication date: December 2020Source: Materials Today Communications, Volume 25Author(s): Ananda Danagoudar, Pratap G K, Manjula Shantaram, Biji Chatterjee, Krishna Ghosh, Santosh R. Kanade, Chandrashekhar G. Joshi
CONCLUSION: The therapeutic benefit of additional substances is less distinct in patients with RAS mutated as compared to RAS wildtype metastatic colorectal cancer, especially with regard to OS. PMID: 32561975 [PubMed - indexed for MEDLINE]
Conclusions: PS ≥ 1, neutrophil count, PLT, andK level were important risk factors for GC therapy-induced hematological toxicity in patients with UC. To continue GC therapy, further management systems by hematological toxicity risk factors for patients with UC will be required.Chemotherapy
Background: Invasive breast cancer (IBC) can be categorized into prognostic and predictive molecular subtypes (including luminal breast cancer) using gene expression profiling. Luminal IBC comprises a variety of histological subtypes with varying clinical and pathological features.Summary: IBC of no special subtype is the most common histological subtype in general and likewise within luminal IBC. Classical invasive lobular breast cancer, typically clustering into luminal subgroup, is characterized by discohesive growth and loss of E-cadherin expression. Infrequent, morphologically distinct luminal IBC subtypes are tubular...
Publication date: Available online 13 July 2020Source: The Annals of Thoracic SurgeryAuthor(s): Sabin J. Bozso, Jeevan Nagendran, Michael W.A. Chu, Bob Kiaii, Ismail El-Hamamsy, Maral Ouzounian, Jörg Kempfert, Christoph Starck, Michael C. Moon
Publication date: Available online 13 July 2020Source: Redox BiologyAuthor(s): Hitoshi Endo, Satoshi Owada, Yutaka Inagaki, Yukari Shida, Masayuki Tatemichi
More News: Cancer | Cancer & Oncology | Carcinoma | Clear Cell Carcinoma | Colorectal Cancer | Endometrial Cancer | Endometriosis | Epithelial Cancer | Gastroschisis Repair | Genetics | HNPCC | Lynch Syndrome | Mucinous Carcinoma | Mucinous Ovarian Cancer | Ovarian Cancer | Ovaries | Pathology | Serous Carcinoma